Clinical worsening events during PATENT-2
| Former riociguat | Former placebo | Total | ||
| 2.5 mg maximum | 1.5 mg maximum | |||
| Patients | 231 | 56 | 109 | 396 |
| Patients with clinical worsening# | 49 (21) | 11 (20) | 24 (22) | 84 (21) |
| Heart/lung transplantation | 1 (0.4) | 1 (2) | 0 | 2 (1) |
| Hospitalisation due to PH | 25 (11) | 5 (9) | 11 (10) | 41 (10) |
| Start of new PH treatment | 34 (15) | 9 (16) | 17 (16) | 60 (15) |
| Decrease in 6MWD due to PH | 6 (3) | 1 (2) | 3 (3) | 10 (3) |
| Persistent worsening in WHO FC due to PH | 4 (2) | 0 | 1 (1) | 5 (1) |
| Died | 14 (6) | 4 (7) | 9 (8) | 27 (7) |
Data are presented as n or n (%). PH: pulmonary hypertension; 6MWD: 6-min walking distance; WHO: World Health Organization; FC: functional class. #: one patient can experience more than one type of event. The mean treatment duration was 95 weeks.